Obtain Real World Insights of Acquired Hemophilia A Patients in Japan

Obtain Real World Insights of Acquired Hemophilia A Patients in Japan - ORIHIME study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043479

Enrollment

200

Registered

2021-03-01

Start date

2021-03-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired hemophilia A

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acquired hemophilia A

Exclusion criteria

Exclusion criteria: Patients with antiphospholipid syndrome, lupus anticoagulant, acquired coagulation factor XIII deficiency, autoimmune acquired Von Willebrand's disease, acquired factor V deficiency

Design outcomes

Primary

Measure	Time frame
-Initial use status of hemostatic agents: amount used, number of times used, number of days used according to type -Use status of immunosuppressants: amount used, number of times used, number of days used according to type -Onset of thromboembolism -Deaths	—

Secondary

Measure	Time frame
Epidemiology -Breakdown of concurrent diseases: malignant tumors, autoimmune diseases. skin diseases, others and pregnancy, delivery at around the time of AHA diagnosis -Age distribution, sex distribution at the time of diagnosis -Breakdown of hospital departments at the time of diagnosis Hospitalizations -Number of hospitalizations -Hospitalization period Treatment implementation status -Transfusion implementation status -Implementation status of plasmapheresis -Implementation status of rehabilitation Outcome -Hemorrhage -Onset of infections -Activities of daily living (ADL) at admission and at discharge -Breakdown of concurrent diseases with deaths -Death risk factor analysis -Infection risk factor analysis -Thromboembolism risk factor analysis	—

Measure

Time frame

Epidemiology -Breakdown of concurrent diseases: malignant tumors, autoimmune diseases. skin diseases, others and pregnancy, delivery at around the time of AHA diagnosis -Age distribution, sex distribution at the time of diagnosis -Breakdown of hospital departments at the time of diagnosis Hospitalizations -Number of hospitalizations -Hospitalization period Treatment implementation status -Transfusion implementation status -Implementation status of plasmapheresis -Implementation status of rehabilitation Outcome -Hemorrhage -Onset of infections -Activities of daily living (ADL) at admission and at discharge -Breakdown of concurrent diseases with deaths -Death risk factor analysis -Infection risk factor analysis -Thromboembolism risk factor analysis

—

Countries

Japan

Contacts

Public ContactYoshinori Imokawa

A2 Healthcare Corporation GPSP Division and Data Science Division

imokawa-y@a2healthcare.com03-3830-1088

Outcome results